论文部分内容阅读
目的评价吡柔比星(THP)、丝裂霉素C(MMC)40 mg、丝裂霉素C 10 mg膀胱灌注预防膀胱肿瘤术后复发的疗效和安全性。方法将近期收治的86例膀胱肿瘤术后患者分为3组,分别接受THP、MMC治疗,随访12~20个月。结果 THP组26例,复发2例,复发率7.7％;MMC组26例,复发3例,复发率11.5％;MMC组31例,复发11例,复发率35.5％。THP组与MMC组相比差异无显著性(P>0.05),而THP组和40mgMMC组与MMC组相比则差异有显著性(P<0.05)。结论吡柔比星和丝裂霉素C 40 mg膀胱灌注预防膀胱肿瘤术后复发效果满意,优于丝裂霉素C 10 mg膀胱灌注。
Objective To evaluate the efficacy and safety of intravesical instillation of pirarubicin (THP), mitomycin C (MMC) 40 mg and mitomycin C 10 mg in preventing postoperative recurrence of bladder cancer. Methods 86 cases of bladder cancer treated recently were divided into 3 groups, receiving THP and MMC respectively and followed up for 12 to 20 months. Results In the THP group, 26 cases were relapsed in 2 cases and the recurrence rate was 7.7%. In the MMC group, 26 cases were recurrence in 3 cases, the recurrence rate was 11.5%. In the MMC group, 31 cases were recurrence and the recurrence rate was 35.5%. There was no significant difference between THP group and MMC group (P> 0.05), but there was significant difference between THP group and 40 mg MMC group and MMC group (P <0.05). Conclusion Intravesical instillation of pirarubicin and mitomycin C 40 mg is effective in preventing postoperative recurrence of bladder cancer, which is superior to intravesical instillation of mitomycin C 10 mg.